<i>BRAF</i> mutations, primarily sensitizing mutations, such as <i>BRAF<sup>V600E</sup></i> , have been proven to response to the <i>BRAF</i> inhibitor, Dabrafenib combined with trametinib therapy, but there have been no data demonstrating that it has activity against NSCLC-related brain metastases (BM). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.